Clorox Co /De/ (CLX) Stock Price & Analysis
Clorox Co /De/ (CLX) fell 1.30% to USD 93.06 as of September 8, 2026 at 06:54 UTC, according to Nexqual real-time market data.
CLX last closed at USD 94.29; the session ranged USD 92.63–94.18 on volume of 2,202,858 shares. Market capitalization is $11.25B, with a 52-week range of USD 84.7–128.9 (NYQ). Source: Nexqual, September 8, 2026 at 06:54 UTC.
Key Statistics (as of September 8, 2026 at 06:54 UTC)
| Price | USD 93.06 |
|---|---|
| Change | ▼ 1.30% (down) |
| Previous Close | USD 94.29 |
| Open | USD 93.75 |
| Day Range | USD 92.63 – 94.18 |
| 52-Week Range | USD 84.7 – 128.9 |
| Volume | 2,202,858 shares |
| Market Cap | $11.25B |
| Exchange | NYQ |
Technical Analysis (CLX)
Nexqual's technical model rates CLX "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.3 (neutral) |
| vs SMA50 | Below (USD 99.86) |
| MACD | -1.67 (negative) |
Analyst Ratings (CLX)
Wall Street analysts rate CLX "Hold" based on 17 analysts, with a mean price target of USD 101.65 (range USD 77–154), per Nexqual as of September 8, 2026 at 06:54 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 101.65 |
| High Target | USD 154 |
| Low Target | USD 77 |
| Buy / Hold / Sell | 1 / 14 / 4 |
Earnings (CLX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 1.11 |
| Revenue Estimate | $1.88B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.66 vs est 1.65 ▲ beat |
| 2026-03-31 | USD 1.64 vs est 1.54 ▲ beat |
| 2025-12-31 | USD 1.39 vs est 1.43 ▼ miss |
| 2025-09-30 | USD 0.85 vs est 0.78 ▲ beat |
Source: Nexqual, September 8, 2026 at 06:54 UTC.
Financials & Fundamentals (CLX)
| Total Revenue | $6.72B |
|---|---|
| Revenue Growth (YoY) | -2.00% |
| Gross Margin | +42.32% |
| Operating Margin | +12.88% |
| Profit Margin | +8.73% |
| ROE | +163.76% |
| Debt / Equity | 2,221.43 |
| Current Ratio | 0.66 |
| Total Cash | $143.00M |
| Total Debt | $5.60B |
| Free Cash Flow | $110.38M |
Source: Nexqual, September 8, 2026 at 06:54 UTC.
Financial Health Score (CLX)
Nexqual rates Clorox Co /De/'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 06:54 UTC.
| Growth | Weak — Revenue -5% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 42%, operating 13% |
| Balance Sheet | Critical — $143M cash vs $5.60B debt |
| Cash Flow | Mixed — FCF $110M, slim 1.6% margin |
| Efficiency | Strong — ROE 164%, ROA 8.3% |
Ownership (CLX)
| Insider Ownership | +0.72% |
|---|---|
| Institutional Ownership | +88.44% |
| Shares Outstanding | 120.93M |
| Float | 120.53M |
| Short % of Float | +11.42% |
Source: Nexqual, September 8, 2026 at 06:54 UTC.
Leadership (CLX)
Clorox Co /De/ is led by Linda J. Rendle (age 47), CEO & Chairman, per Nexqual as of September 8, 2026 at 06:54 UTC.
| CEO & Chairman | Linda J. Rendle (age 47) |
|---|---|
| Executive VP & CFO | Luc Bellet (age 46) |
| Executive VP & COO | Chris T. Hyder (age 50) |
| Vice President of Investor Relations | Lisah Burhan |
| Senior VP & Chief Marketing Officer | Eric Sean Schwartz (age 53) |
Major Backers & Investors (CLX)
Notable institutional backers of Clorox Co /De/ include Invesco, Van Eck Associates Corporation, VanEck ETF Trust-VanEck Morningstar Wide Moat ETF, according to Nexqual as of September 8, 2026 at 06:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 6.52% |
| Van Eck Associates Corporation | 2.46% |
| VanEck ETF Trust-VanEck Morningstar Wide Moat ETF | 2.18% |
| Morgan Stanley | 1.86% |
| Millennium Management | 1.71% |
| UBS Group AG | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.84% |
| BlackRock | 9.69% |
| State Street | 6.97% |
| Geode Capital | 2.7% |
Source: Nexqual, September 8, 2026 at 06:54 UTC.
From Clorox Co /De/'s Latest SEC 10-K Filing (filed 2026-08-07)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company also markets industry-leading products and technologies for professional customers, including those sold under the Purell ® , CloroxPro ™ and Clorox Healthcare ® brand names.
- The ERP system implementation, which was completed in January 2026, has required, and will continue to require, investment of personnel and financial resources to support post-implementation efforts and system functionality.
Partnerships
- The Company's venture agreement with The Procter & Gamble Company (P&G) for the Company's Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026.
- In connection with the expiration of the Venture Agreement, the Company was required to purchase P&G's 20% interest in the business at fair value.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMB | Kimberly-Clark Corporation | USD 104.96 | ▼ 3.96% |
| CL | Colgate-Palmolive Company | USD 88.77 | ▼ 1.48% |
| GIS | General Mills, Inc. | USD 38.29 | ▼ 5.64% |
| MKC | McCormick & Company, Incorporat | USD 52.08 | ▼ 3.2% |
| HRL | Hormel Foods Corporation | USD 21.54 | ▼ 2.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:54 UTC. This page is informational and not investment advice.